

Consistent baseline characteristics across both the ASPEN and WILLOW trials

Characteristics	ASPEN ¹	WILLOW
Number of patients	1,682*	256
Mean age (yrs)	61.3	64.1
≥ 75 years (n, %)	262, 15.6%	48, 18%
Female (n, %)	1,089, 64.7%	174, 67.9%
Number of patients with history of COPD as secondary** (n, %)	241, 14.3%	42, 16.4%
Number of patients with history of asthma as secondary** (n, %)	302, 17.9%	64, 25%
Pseudomonas aeruginosa positive (n, %)	589, 35.0%	89, 34.8%
Chronic macrolide use (n, %)	285, 16.9%	40, 15.6%
≥3 exacerbations in prior 12 months (n, %)	492, 29.3%	84, 32.8%
2 exacerbations in prior 12 months (n, %)	1,190, 70.7%	172, 67.2%

* Evaluable adult subjects

**As reported by medical history

¹ Represents preliminary figures